Category: Press Releases

Up to an Additional $46.2 Million Available Through Warrant Exercise

Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital Partners

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced it has signed a securities purchase agreement with a syndicate of healthcare-focused institutional investors that have agreed to provide initial upfront funding of $28.0 million in gross proceeds to Telesis Bio through a private placement of redeemable convertible preferred stock. The private placement also includes the issuance of warrants that, if cash exercised, would provide Telesis Bio with another $46.2 million in gross proceeds.

The financing is led by Novalis LifeSciences LLC with participation from Northpond Ventures, BroadOak Capital Partners and M-185 Corporation, an affiliate of the Company’s Chief Executive Officer and Founder, Todd R. Nelson, PhD.

Under the terms of the Redeemable Convertible Preferred Stock and Warrant Purchase Agreement, immediately following the closing of the financing, Paul Meister, a partner at Novalis LifeSciences LLC, will be appointed to the Company’s board of directors, increasing the size of its board of directors from seven to eight.

“We are pleased to announce this financing led by Novalis LifeSciences LLC with strong support from existing investors,” shared Todd R. Nelson, CEO and Founder of Telesis Bio. “Paul Meister’s tenure in the industry as a veteran executive and board member at notable companies such as Syneos Health, Fisher Scientific and ThermoFisher Scientific, will be a valuable asset to the shareholders of Telesis Bio as we seek to increase shareholder value and approach profitability in the 2024 timeframe.”

“The company’s innovative BioXp automation solutions are still in the early stages of adoption within targeted discovery workflows including biologics, cell and gene therapy and genome engineering. The value proposition to researchers will only continue to increase as the demands within the multi-omics and synthetic biology markets continues,” stated Paul Meister. “I am grateful for the opportunity to join this esteemed board of directors and support the Company’s vision for the BioXp platform.”

“While we believe strongly in our ability to grow our BioXp installed base and are confident that we can achieve our long-term revenue and profitability goals, we are adjusting expectations for the company’s financial performance for the remainder of 2023, as we continue to see challenging headwinds that may impact our revenue results,” Nelson shared. “We now anticipate full year revenue for the company to be approximately $35 million and operating expenses, including non-cash and one-time charges to be approximately $55 million. Gross margin expectations of approximately 57% remain unchanged.”

The Company intends to use the proceeds from the financing for general corporate purposes. The financing is expected to close on June 2, 2023, subject to the satisfaction of customary closing conditions.

Please refer to the Company’s Form 8-K to be filed with the Securities and Exchange Commission for the complete terms of the financing.

THIS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITY. THE SECURITIES OFFERED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR ANY STATE THEREOF ABSENT REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR AN APPLICABLE EXEMPTION FROM REGISTRATION REQUIREMENTS.

About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com.

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

About Novalis LifeSciences LLC

Novalis LifeSciences LLC is a boutique investment and advisory firm for the Life Science industry. With a team of experienced operating executives from the industry, Novalis funds and advises visionary Life Science entrepreneurs. For more information visit www.novalislifesciences.com.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio’s future financial performance, the completion, timing and size of the financing, the anticipated use of proceeds from the financing, as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission (SEC) on March 22, 2023, as amended on May 17, 2023 and in our Quarterly Report on Form 10-Q, which was filed with the SEC on May 12, 2023. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

Contact:
Jen Carroll
Vice President of Investor Relations
jen.carroll@telesisbio.com

GlobeNewswire Distribution ID 8850124

PHOENIX, May 31, 2023 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), the North American leader in innovative flexible space and storage solutions, today announced that Brad Soultz, Chief Executive Officer, and Nick Girardi, Senior Director of Treasury and Investor Relations, will participate in a presentation and host private investor meetings at the Wells Fargo Industrials Conference in Chicago, IL, on June 14, 2023. The presentation will take place at 10:15 am CT.

About WillScot Mobile Mini

WillScot Mobile Mini trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible space and storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 240 branch locations and additional drop lots throughout the United States, Canada, and Mexico.

Additional Information and Where to Find It

Additional information can be found on the company’s website at www.willscotmobilemini.com.

Contact Information
Investor Inquiries:		Media Inquiries:
Nick Girardi		Jake Saylor
investors@willscotmobilemini.com		jake.saylor@willscot.com

GlobeNewswire Distribution ID 8844366

CHEMNITZ, Germany, May 31, 2023 (GLOBE NEWSWIRE) — BASELABS, the specialist for sensor fusion, is now offering the acquisition of its complete software IP in the field of environment perception for automated driving in ASIL D. In contrast to the previous licensing model, buyers of the IP will be able to use the software without restrictions. The high maturity of the BASELABS technologies enables their use in safety-critical applications for highly automated systems such as L4 vehicles and high-volume driver assistance applications (ADAS). The acquisition of the technologies can be exclusive or partially exclusive. Interested companies can register for the sales process directly with BASELABS at ip@baselabs.de.

The BASELABS portfolio includes BASELABS Dynamic Grid, the latest low-level sensor fusion technology ready for series production, which is particularly suitable for high-resolution sensors and complex driving environments. Furthermore, BASELABS Create Embedded, a library optimized over many years for embedded use, can be acquired mainly for NCAP functions. Both products include a complete development and validation infrastructure and all process artifacts required for use in series production.

“The outstanding customer feedback on our technologies over many years motivated us now to offer the model of ownership of our software IP requested by many market participants. Buyers of our software will receive safety-certified technologies for the vehicles of tomorrow and thus increase the safety of automated traffic worldwide,” says Robin Schubert, Managing Director of BASELABS.

Image caption: The Dynamic Grid is one of the available BASELABS technologies. It enables safe environment perception and is a fundamental component of safe software architectures for highly automated driving.

Download Screenshot

About BASELABS

BASELABS is executing on the vision of “safe automated driving for all vehicles.” The company provides software IP to enhance the performance of environment awareness and strengthens the strategic position of its customers in the race for the “software-defined vehicle.” BASELABS is a trustworthy partner for automotive manufacturers and suppliers worldwide. The company was founded in 2012 and is owned by Vector Informatik GmbH. Thus, it is strategically independent of any OEM, Tier 1, or sensor supplier in the market.

A picture accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2f5ee054-1ffe-4acb-ae82-965c6c3f5e1d

A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/75e64e15-de97-47d9-8d4c-49d6e460c0b1

Press Contact:

Holger Löbel, Director and Co-Founder 
Tel.:+49 (0) 371 3371 51 21 
Email:holger.loebel@baselabs.de  
https://www.baselabs.de  
Tel.: +49 (0) 371 3371 51 21 
Email: holger.loebel@baselabs.de 
https://www.baselabs.de

GlobeNewswire Distribution ID 1000823022.

BERLIN, May 31, 2023 (GLOBE NEWSWIRE) — BERLINER TAGESZEITUNG reports today that a criminal complaint has been filed against Elon Musk with the Berlin public prosecutor’s office, file number: 253 UJs 1012/23, alleging that Musk charged Twitter users’ credit cards but suspended verified Twitter accounts without giving any reason.

Source: https://www.BerlinerTageszeitung.de/wirtschaft/269895-criminal-complaint-in-berlin-germany-against-elon-musk-and-twitter-for-possible-fraud-to-the-detriment-of-twitter-users.html

“Blocking user accounts is a daily occurrence at Twitter, but the fact that they then continuously charge money to users’ credit cards makes the matter explosive and is currently occupying the Berlin Public Prosecutor’s Office (Federal Republic of Germany). In any case, the question arises as to how much power a medium like Twitter can be granted at all and when the regulatory authorities should intervene to protect Twitter users.”

Incidentally, this is not the first time Elon Musk has been investigated, as there is also currently an investor lawsuit against Tesla CEO Elon Musk. The lawsuit is about Musk’s tweets in August 2018 with the premature announcement that he wanted to take the electric car company off the stock market and had secured the financing to do so. It later emerged that there were no firm commitments from investors.

“Elon Musk lied,” said a lawyer for the plaintiffs.

US Judge Edward Chen (Judge of the United States District Court for the Northern District of California) had already found in the 2022 trial that Musk’s statements in the tweets had not been true.

“We will continue to monitor the case closely and report further developments as new information becomes available. It remains to be seen how the criminal charges against Elon Musk and Twitter will develop and what the consequences might be.”

From a factual point of view, it should be noted that according to Article 48 of the Charter of Fundamental Rights of the European Union, the presumption of innocence applies to defendants and accused persons, which must also apply in the case of the criminal charges against Elon Musk for “suspected fraud to the detriment of Twitter users”.

META KEYS: Elon Musk, Elon Musk Twitter, Elon Musk Strafanzeige, Twitter accounts, Thierry Breton, Thierry Breton Twitter, Berlin public prosecutor’s office against Elon Musk, Twitter users, BERLINER TAGESZEITUNG, verified Twitter accounts

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f3c50532-be3a-4bad-8e85-7253731d594c

Press Contact:
BERLINER TAGESZEITUNG
Press Contact: P. Hansen
Unter den Linden 21
10117 Berlin
Germany
Mail: Info@DeutscheTageszeitung.de
Web: http://www.DeutscheTageszeitung.de

GlobeNewswire Distribution ID 8849934

Press Contact:

BERLINER TAGESZEITUNG
Press Contact: P. Hansen
Unter den Linden 21
10117 Berlin
Germany
Mail: Info@DeutscheTageszeitung.de
Web: http://www.DeutscheTageszeitung.de